文献速递前列腺癌

完整PSA与hK2在4种激肽释放酶预测模型中的价值:个体患者数据Meta分析

Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.
PubMed 文献 · J Urol · 2018-01-31

该个体患者数据Meta分析纳入10项研究共14,510名接受前列腺活检的男性,评估在包含总PSA和游离PSA的统计模型中加入完整PSA和hK2对判别力的改善。不含完整PSA和hK2的模型判别力为0.742(95%CI 0.727-0.756),完整激肽释放酶模型为0.813(95%CI 0.801-0.825),差异0.069(95%CI 0.057-0.080,p<0.0001)。完整PSA和hK2各自独立增加判别力。

要点

  • 完整激肽释放酶模型判别高级别前列腺癌的AUC为0.813,高于不含完整PSA和hK2模型的0.742。
  • 完整PSA独立增加判别力0.059(95%CI 0.050-0.069),hK2独立增加0.024(95%CI 0.020-0.029)。
  • 不测量完整PSA和hK2时,仅用常规数据无法复现该模型的临床价值。

核心结论

  • 不测量完整PSA和hK2,仅用泌尿外科医生常规可获数据无法复现4种激肽释放酶面板的临床价值。

研究设计与样本

  • 个体患者数据Meta分析,纳入10项已发表研究共14,510名接受前列腺活检的男性。

主要发现

  • 固定效应Meta分析估计,不含完整PSA和hK2的模型判别力为0.742(95%CI 0.727-0.756),完整激肽释放酶模型为0.813(95%CI 0.801-0.825),差异0.069(95%CI 0.057-0.080,p<0.0001)。
  • 完整PSA增加判别力0.059(95%CI 0.050-0.069),hK2增加判别力0.024(95%CI 0.020-0.029),各自p<0.0001,均独立贡献于模型。

临床怎么用

  • 使用4Kscore®等4种激肽释放酶面板预测高级别前列腺癌时,需包含完整PSA和hK2的检测。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The 4 kallikrein panel, commercially available as the 4Kscore®, is a statistical model that has been shown to accurately predict Gleason Grade Group 2 or greater (high grade) cancer on biopsy and the long-term risk of distant prostate cancer metastases. The panel includes 2 novel markers, namely intact prostate specific antigen and hK2. It has been questioned whether these 2 additional markers add discrimination to the clinical predictors of patient age, digital rectal examination and prior biopsy, and the established molecular markers total and free prostate specific antigen. MATERIALS AND METHODS: We performed an individual patient data meta-analysis of published studies in which the 4 kallikrein panel was measured in men undergoing prostate biopsy. We assess the improvement in discrimination associated with including intact prostate specific antigen and hK2 along with total and free prostate specific antigen in the statistical model. RESULTS: Included in analysis were 14,510 men from a total of 10 studies. The fixed effects meta-analytical estimate of the discrimination of the model without intact prostate specific antigen and hK2 was 0.742 (95% CI 0.727-0.756) compared to 0.813 (95% CI 0.801-0.825) for the full kallikrein model. The 95% CIs did not overlap and the difference in discrimination was highly statistically significant (0.069, 95% CI 0.057-0.080, p <0.0001). Intact prostate specific antigen (increase in discrimination 0.059, 95% CI 0.050-0.069) and hK2 (increase in discrimination 0.024, 95% CI 0.020-0.029, each p <0.0001) added independently to the model. CONCLUSIONS: The clinical value of the panel could not be replicated using data readily available to urologists without measuring intact prostate specific antigen and hK2.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Vickers A, Vertosick EA, Sjoberg DD, et al. Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis. J Urol. 2018. PMID: 29366640. doi:10.1016/j.juro.2018.01.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。